Platelet Transfusion Guidelines: Thresholds, Product Types, and Clinical Scenarios (เมื่อไหร่เติมเกล็ดเลือด)

Introduction

Platelets play a vital role in primary hemostasis, and thrombocytopenia (low platelet count) increases the risk of spontaneous bleeding. Clinical decision-making for platelet transfusion depends on both platelet count and the patient’s clinical status, particularly the presence or absence of bleeding.

1. Platelet Transfusion Guidelines Based on Clinical Status

A. Stable Patients Without Active Bleeding

Threshold: 50,000/µL
Indications include:
- Preparing for invasive procedures (e.g., central line placement, lumbar puncture)
- Presence of conditions like immune thrombocytopenic purpura (ITP) or bone marrow suppression, but with no ongoing hemorrhage.
Rationale: At this level, spontaneous bleeding is uncommon; transfusion is precautionary or preventive.

B. Patients with Active Bleeding or High Risk of Bleeding

Threshold: 30,000/µL
- For patients with minor but active bleeding or those at moderate risk (e.g., fever, coagulopathy, recent surgery, sepsis).
Threshold: 10,000/µL
- For patients who are not actively bleeding and have no significant risk factors, often used in oncology/hematology for prophylaxis.
Threshold: >50,000–100,000/µL
- Required for major surgeries, especially involving critical areas such as the brain or eyes.

🔎 Note: Transfusion thresholds may be individualized based on specific guidelines (e.g., ASH, AABB, Thai CPG) and patient context.

2. Platelet Concentrate Transfusion Strategy

1 unit of platelet concentrate typically increases the platelet count by:
- 5,000–10,000/µL in an average adult.
Dose calculation: Usually 1 unit per 10 kg body weight or a fixed dose of 4–6 pooled units (whole blood-derived) or 1 apheresis unit.

Product Options:

Random donor platelets (RDP): From whole blood, pooled for transfusion.
Single donor platelets (SDP): From apheresis, contain larger platelet yield.

3. Monitoring and Post-Transfusion Care

Recheck CBC/platelet count 1 hour and 24 hours post-transfusion to assess response.
Platelet refractoriness should be considered if there's inadequate response. Causes include:
- Immune causes (e.g., HLA alloimmunization)
- Non-immune causes (e.g., fever, sepsis, DIC)

4. Practical Scenarios

Scenario	Transfusion Threshold	Notes
Stable, asymptomatic	<10,000/µL	Prophylactic
Stable, undergoing minor surgery	<50,000/µL	Invasive procedures
Active GI bleeding	<30,000–50,000/µL	Raise platelets
Neurosurgery or eye surgery	<100,000/µL	High-risk area
Hematologic malignancy, afebrile	<10,000/µL	Routine oncology prophylaxis

5. Clinical Take-Home Points

Always assess clinical context, not just numbers.
Avoid unnecessary transfusions in stable patients to reduce alloimmunization risks.
Use correct platelet product and monitor response.
Consider local hospital guidelines and CPGs (e.g., Thailand National List of Essential Medicines) in resource-limited settings.